MedTrace Logo

Use of DNAse in Neutrophilic Asthma

NCT03994380 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-20

No results posted yet for this study

Summary

In this pilot protocol, the researchers look to determine benefits from use of nebulized rh-DNase for 4 weeks in patients with neutrophilic asthma.

Conditions

  • Neutrophilic Asthma

Interventions

DRUG

RhDNAse Inhalation Solution

rhDNAse 2.5 mg nebulizer daily for 4 weeks

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2022-05-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03994380 on ClinicalTrials.gov